Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass

Journal of Bone and Mineral Research

Volumn 32, Issue 1, 2017, Pages 181-187

  Genant, Harry K ^a,b   Engelke, Klaus ^c,d   Bolognese, Michael A ^e   Mautalen, Carlos ^f   Brown, Jacques P ^g   Recknor, Chris ^h   Goemaere, Stefan ⁱ   Fuerst, Thomas ^c   Yang, Yu Ching ^j   Grauer, Andreas ^j   Libanati, Cesar ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SYNARC INC   (United States)

^c BioClinica Inc   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e Bethesda Health Research Center   (United States)

^f Centro de Osteopatias Medicas   (Argentina)

^g University Laval   (Canada)

^h United Osteoporosis Centers   (United States)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j AMGEN INC   (United States)

^k UCB PHARMA   (Belgium)

more..

Author keywords

ANABOLICS; BONE QCT; CLINICAL TRIALS; OSTEOPOROSIS

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; ROMOSOZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TRABECULAR BONE; TREATMENT DURATION; ANATOMY AND HISTOLOGY; CLINICAL TRIAL; COMPARATIVE STUDY; DEMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFECTS; LUMBAR VERTEBRA; MIDDLE AGED; ORGAN SIZE; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; POSTMENOPAUSE; SPINE; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BONE DENSITY; DEMOGRAPHY; FEMALE; HIP; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; ORGAN SIZE; POSTMENOPAUSE; SPINE; TERIPARATIDE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84992500359     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2932     Document Type: Article

References (26)

1. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24(4):578–88.
2. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010; 25(12):2647–56.
3. Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014; 54(2):168–78.
4. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26(1):19–26.
5. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370(5):412–20.
6. Carballido-Gamio J, Harnish R, Saeed I, et al. Proximal femoral density distribution and structure in relation to age and hip fracture risk in women. J Bone Miner Res. 2013; 28(3):537–46.
7. Kim KM, Brown JK, Kim KJ, et al. Differences in femoral neck geometry associated with age and ethnicity. Osteoporos Int. 2011; 22(7):2165–74.
8. Sornay-Rendu E, Cabrera-Bravo JL, Boutroy S, Munoz F, Delmas PD. Severity of vertebral fractures is associated with alterations of cortical architecture in postmenopausal women. J Bone Miner Res. 2009; 24(4):737–43.
9. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int. 2003; 14 Suppl 3:S13–8.
10. Brandi ML. Microarchitecture, the key to bone quality. Rheumatology (Oxford). 2009; 48 Suppl 4:iv3–8.
11. Steiniche T, Christiansen P, Vesterby A, et al. Marked changes in iliac crest bone structure in postmenopausal osteoporotic patients without any signs of disturbed bone remodeling or balance. Bone. 1994; 15(1):73–9.
12. Engelke K, Adams JE, Armbrecht G, et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom. 2008; 11(1):123–62.
13. Engelke K, Libanati C, Fuerst T, Zysset P, Genant HK. Advanced CT based in vivo methods for the assessment of bone density, structure, and strength. Curr Osteoporos Rep. 2013; 11(3):246–55.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461–70.
15. Museyko O, Bousson V, Adams J, Laredo JD, Engelke K. QCT of the proximal femur-which parameters should be measured to discriminate hip fracture? Osteoporos Int. 2016; 27(3):1137–47.
16. Engelke K, Mastmeyer A, Bousson V, Fuerst T, Laredo JD, Kalender WA. Reanalysis precision of 3D quantitative computed tomography (QCT) of the spine. Bone. 2009; 44(4):566–72.
17. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165(15):1762–8.
18. Damm T, Libanati C, Peña J, et al. Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide: HR-QCT analyses of randomized controlled trial results in postmenopausal women with low BMD. J Bone Miner Res. 2014;29 Suppl 1. [Poster session presented at: Annual Meeting American Society for Bone and Mineral Research (ASBMR); 2014 Sep 12–15; Houston, TX, USA; Presentation Numbers: FR0380 and SA0380]. Available from: http://www.asbmr.org/education/AbstractDetail?aid=5e893e80-e722-4244-a147-7602da91e9a2
19. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. 2007; 41(3):321–30.
20. Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int. 2011; 22(1):357–62.
21. Ominsky MS, Niu QT, Li C, Li X, Ke HZ. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res. 2014; 29(6):1424–30.
22. Niu Q-T, Boyce RW, Ominsky MS. Romosozumab (sclerostin antibody) increases wall thickness in remodeling units in cynomolgus monkeys after 28 weeks. J Bone Miner Res. 2015;30 Suppl 1. [Poster session presented at: Annual Meeting American Society for Bone and Mineral Research (ASBMR); 2015 Oct 9–12; Seattle, WA, USA; Presentation Numbers: MO0030 and LB-MO0030]. Available from: http://www.asbmr.org/education/AbstractDetail?aid=c1d1c297-1e81-4ca2-b6c3-bbb55f6c5706
23. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011; 26(5):1012–21.
24. Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res. 2010; 25(12):2558–71.
25. Engelke K, Fuerst T, Dasic G, Davies RY, Genant HK. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. Bone. 2010; 46(6):1626–32.
26. Rizzoli R, Chapurlat RD, Laroche JM, et al. Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int. 2012; 23(1):305–15.